Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$2.0M
Filings
88
Firms Hired
2
Active Period
2015–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Client expense: $60,000 · Firm income: —
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Client expense: $60,000 · Firm income: —
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Client expense: $60,000 · Firm income: —
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Client expense: $60,000 · Firm income: —
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Client expense: $60,000 · Firm income: —
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Client expense: $60,000 · Firm income: —
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Client expense: $50,000 · Firm income: —
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Client expense: $50,000 · Firm income: —
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Client expense: $50,000 · Firm income: —
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Client expense: $50,000 · Firm income: —
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Client expense: $50,000 · Firm income: —
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Client expense: $50,000 · Firm income: —
Matched citations: S. 934
Small Manufacturer Protection Act of 2013
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: HR 3631
Small Manufacturer Protection Act of 2013
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: HR 3631
Small Manufacturer Protection Act of 2013
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: HR 3631
21st Century Cures Act
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 6
21st Century Cures Act
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 6
21st Century Cures Act
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 6
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: S. 3187
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: S. 3187
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
2015 · second_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Client expense: $10,000 · Firm income: —
Matched citations: S. 3187
Small Manufacturer Protection Act of 2013
2015 · first_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Client expense: $20,000 · Firm income: —
Matched citations: HR 3631
Small Manufacturer Protection Act of 2013
2015 · first_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Client expense: $20,000 · Firm income: —
Matched citations: HR 3631
Small Manufacturer Protection Act of 2013
2015 · first_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Client expense: $20,000 · Firm income: —
Matched citations: HR 3631
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
2015 · first_quarter · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Client expense: $20,000 · Firm income: —
Matched citations: S. 3187
Source: Senate LDA